Association of the MDM2 SNP285 Polymorphism with Cancer Susceptibility: A Meta-Analysis
Table 2
Meta-analysis of the association between MDM2 SNP285 polymorphism and cancer risk.
Variables
Number of studies
Heterozygous
Dominant
Allele comparison
GC versus GG
(CC+GC) versus GG
C versus G
OR (95% CI)
I2 (%)
OR (95% CI)
I2 (%)
OR (95% CI)
I2 (%)
All1
15
0.89 (0.79–0.99)
0.120
31.2
0.90 (0.79–1.01)
0.043
42.2
0.91 (0.80–1.03)
0.014
50.0
Cancer type
Breast
4
0.81 (0.61–1.08)
0.074
56.8
0.84 (0.61–1.15)
0.033
65.7
0.87 (0.62–1.22)
0.015
71.4
Lung
3
1.07 (0.86–1.34)
0.676
0.0
1.09 (0.87–1.36)
0.726
0.0
1.10 (0.89–1.37)
0.773
0.0
Prostate
2
1.02 (0.84–1.25)
0.664
0.0
1.06 (0.87–1.30)
0.677
0.0
1.10 (0.91–1.34)
0.700
0.0
Ovarian
2
0.77 (0.63–0.94)
0.903
0.0
0.76 (0.63–0.93)
0.943
0.0
0.77 (0.63–0.93)
0.985
0.0
Others2
4
0.86 (0.66–1.11)
0.175
39.5
0.85 (0.64–1.12)
0.122
48.2
0.84 (0.63–1.14)
0.084
54.8
Ethnicity
Caucasian
13
0.88 (0.79–0.98)
0.088
36.9
0.89 (0.79–1.00)
0.028
47.7
0.90 (0.79–1.03)
0.008
55.2
African
1
1.80 (0.36–9.03)
—
—
1.80 (0.36–9.03)
—
—
1.79 (0.36–8.93)
—
—
Mixed
1
1.76 (0.32–9.79)
—
—
1.76 (0.32–9.79)
—
—
1.74 (0.32–9.62)
—
—
Sample size
<500
6
0.79 (0.51–1.21)
0.079
49.4
0.84 (0.52–1.35)
0.030
59.5
0.89 (0.54–1.47)
0.012
65.8
≥500
9
0.92 (0.84–1.00)
0.525
0.0
0.93 (0.85–1.02)
0.368
8.1
0.94 (0.85–1.04)
0.233
23.6
Vargas-Torres et al. (2014), it was not calculated for these models because the numbers of GC and CC genotypes were zero. 2The others included endometrial cancer [16], hepatocellular carcinoma [19], colon cancer [21], and cervical cancer [22].
